Playback speed
10 seconds
This video is featured in the 2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Nal-IRI/LV5-FU vs. Paclitaxel as 2L Therapy in Metastatic Esophageal SCC - OESIRI-PRODIGE 62 Study
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
David Tougeron
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
David Tougeron
63 views
September 27, 2024
Comments 0
Login to view comments.
Click here to Login